Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 5, 2014, Pages 905-913

  Lee, Taewoo ^a,c   Gasim, Adil ^a   Derebail, Vimal K ^a   Chung, Yunro ^b   McGregor, Julieanne G ^a   Lionaki, Sophia ^d   Poulton, Carolinej ^a   Hogan, Susan L ^a   Jennette, J Charles ^a   Falk, Ronald J ^a   Nachman, Patrick H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c Seoul National University   (South Korea)

^d LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CHRONICITY INDEX SCORE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRANULOMATOSIS; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; LONG TERM CARE; LUNG DISEASE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEVERE RENAL IMPAIRMENT; SURVIVAL; TREATMENT RESPONSE; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPLICATION; END STAGE LIVER DISEASE; GLOMERULONEPHRITIS; GLOMERULUS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CYCLOPHOSPHAMIDE; END STAGE LIVER DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922479887     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08290813     Document Type: Article

References (29)

1. Hedger N, Stevens J, Drey N, Walker S, Roderick P: Incidence and outcome of pauci-immune rapidly progressive glomerulo-nephritis in Wessex, UK: A 10-year retrospective study. Nephrol Dial Transplant 15: 1593–1599, 2000.
2. Sinico RA, Di Toma L, Radice A: Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Au-toimmun Rev 12: 477–482, 2013.
3. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD: ANCA-associated vasculitis with renal involvement: aAn outcome analysis. Nephrol Dial Transplant 19: 1403–1411, 2004.
4. Day CJ, Howie AJ, Nightingale P, Shabir S, Adu D, Savage CO, Hewins P: Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: Quantitative histomorphometric assessment and serum creatinine. Am J Kidney Dis 55: 250–258, 2010.
5. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488–494, 2011.
6. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomer-ulonephritis. J Am Soc Nephrol 7: 23–32, 1996.
7. Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH: The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 76: 644–651, 2009.
8. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L: Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 50: 36–46, 2007.
9. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group: EULARrecommendationsforthemanagementofprimary small and medium vessel vasculitis. Ann Rheum Dis 68: 310–317, 2009.
10. Nachman PH, Reisner HM, Yang JJ, Jennette JC, Falk RJ: Shared idiotypy among patients with myeloperoxidase-anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. Lab Invest 74: 519–527, 1996.
11. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of dietin renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006.
12. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA: 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65: 1–11, 2013.
13. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noe¨l LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM: Histopathologic classification of ANCA-associated glomer-ulonephritis. J Am Soc Nephrol 21: 1628–1636, 2010.
14. Kim HT: Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 13: 559–565, 2007.
15. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF: On the use of cause-specific failure and conditional failure probabilities — examples from clinical oncology data. J Am Stat Assoc 88: 400–409, 1993.
16. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141–1154, 1988.
17. Fine JP, Gray RJ: A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 94: 496–509, 1999.
18. Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, Jayne DR; European Vasculitis Study Group (EUVAS): Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84: 397–402, 2013.
19. De Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM: Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17: 2264–2274, 2006.
20. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC; European Vasculitis Study Group (EUVAS): Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int 62: 1732–1742, 2002.
21. Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard Thomsen B, Dreyer L, Baslund B: Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 60: 1187–1192, 2009.
22. Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, Savage CO, Harper L: Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. Arthritis Rheum 60: 3493–3500, 2009.
23. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Höglund P, Javaid MK, Jayne D, Mukhtyar C, Westman K, Davis JC Jr, Hoffman GS, McCune WJ, Merkel PA, St Clair EW, Seo P, Spiera R, Stone JH, Luqmani R: A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 63: 588–596, 2011.
24. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Bajema IM, Hagen EC, Pusey CD; EUVAS: Chances of renal recovery for dialysis-dependent ANCA-associated glo-merulonephritis. J Am Soc Nephrol 18: 2189–2197, 2007.
25. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621–631, 2005.
26. Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM; European Vasculitis Society: Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after ritux-imab therapy. J Am Soc Nephrol 23: 313–321, 2012.
27. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ,de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as ad-junctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–2188, 2007.
28. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vas-culitis. N Engl J Med 363: 221–232, 2010.
29. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associ-ated renal vasculitis. N Engl J Med 363: 211–220, 2010.